| GH | Guardant Health Inc | 9.09% |
| NTRA | Natera Inc | 7.46% |
| KRYS | Krystal Biotech Inc | 6.33% |
| LGND | Ligand Pharmaceuticals Inc | 4.62% |
| ADPT | Adaptive Biotechnologies Corp | 3.99% |
| UTHR | United Therapeutics Corp | 3.51% |
| BBIO | BridgeBio Pharma Inc | 3.50% |
| LLY | Eli Lilly and Co | 2.95% |
| TWST | Twist Bioscience Corp | 2.85% |
| VRTX | Vertex Pharmaceuticals Inc | 2.75% |
The fund seeks capital appreciation by investing in equity securities inside and outside of the United States, including developing or emerging markets. The fund invests in companies that are relevant to its investment theme of genomic advancements that the investment manager believes are substantially focused on/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business.
Franklin Genomic Advancements ETF · Issued by Franklin Templeton
No recent news for HELX. The ingest cron pulls every 15 minutes during market hours.